BRNS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Barinthus Biotherapeutics PLC (BRNS) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 investment range. The stock shows weak financial performance, no positive news catalysts, bearish technical indicators, and lacks significant trading trends or institutional support. Given the absence of growth prospects and the company's deteriorating fundamentals, it is advisable to avoid this stock.
The technical indicators are bearish. The MACD is below zero and negatively contracting, the RSI is at 37.212 (neutral but leaning towards oversold), and moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support levels are at 0.584 and 0.556, while resistance levels are at 0.63 and 0.676. The stock closed at 0.6, below the pivot level of 0.63, indicating weakness.
NULL identified. No recent news, no positive financial trends, and no significant insider or hedge fund activity.
Revenue dropped to 0 in Q3 2025 (-100% YoY), gross margin dropped to 0 (-100% YoY), and the stock price declined by -4.43% in the last session. The market sentiment is bearish with SP500 down -0.56%.
In Q3 2025, the company reported a 100% YoY decline in revenue (to 0) and gross margin (to 0). Net income improved YoY to -$14.57M (+79.52%), and EPS improved to -0.36 (+71.43%), but these figures remain negative and indicate poor financial health.
No data available for analyst ratings or price target changes.
